Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide to prevent GnRH agonist flare in newly diagnosed metastatic prostate cancer
ChiCTR2300076106Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rezvilutamide in prostate cancer (PCa) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Prostate-specific antigen, Luteinizing hormone and 2 more. Started Oct 2023; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2300076106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076106.